The relation between IDC‐P and germline BRCA2 variant was initially identified in patient‐derived xenografts (PDXs),14 and subsequent germline genetic testing in recurrent or metastatic prostate cancer patients further revealed dysregulation of DNA repair genes (BRCA2, BRCA1, MSH6, PALB2, NBN) and DNA damage sensing genes (ATM, CHEK2, CDH1) in IDC‐P.4, 7, 15. Here, BRCA2 is linked to metastatic prostate carcinoma.